Switch theme
Sign up to access all valuation multiples
Level Bio AB is a parent company and operates through subsidiary. It develops and manufactures diagnostic kits for the clinical market and also is a distributor and full service partner to molecular biology labs in the Nordics.
1975
9
Last FY Revenue $2.6M
Last FY EBITDA -$0.6M
$2.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Level Bio achieved revenue of $2.6M and an EBITDA of -$0.6M.
Level Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Level Bio valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $2.6M | XXX | XXX | XXX |
| Gross Profit | XXX | $1.4M | XXX | XXX | XXX |
| Gross Margin | XXX | 54% | XXX | XXX | XXX |
| EBITDA | XXX | -$0.6M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -24% | XXX | XXX | XXX |
| EBIT | XXX | -$0.8M | XXX | XXX | XXX |
| EBIT Margin | XXX | -32% | XXX | XXX | XXX |
| Net Profit | XXX | -$0.8M | XXX | XXX | XXX |
| Net Margin | XXX | -31% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Level Bio's stock price is SEK 0 (or $0).
Level Bio has current market cap of SEK 26.7M (or $2.8M), and EV of SEK 24.2M (or $2.5M).
See Level Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.5M | $2.8M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Level Bio has market cap of $2.8M and EV of $2.5M.
Level Bio's trades at 1.0x EV/Revenue multiple, and -4.1x EV/EBITDA.
Equity research analysts estimate Level Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Level Bio's P/E ratio is not available.
See valuation multiples for Level Bio and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.8M | XXX | $2.8M | XXX | XXX | XXX |
| EV (current) | $2.5M | XXX | $2.5M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 1.0x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -4.1x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -3.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -3.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -5.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLevel Bio's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Level Bio's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Level Bio's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Level Bio and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -24% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 86% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Level Bio acquired XXX companies to date.
Last acquisition by Level Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . Level Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Level Bio founded? | Level Bio was founded in 1975. |
| Where is Level Bio headquartered? | Level Bio is headquartered in Sweden. |
| How many employees does Level Bio have? | As of today, Level Bio has 9 employees. |
| Is Level Bio publicy listed? | Yes, Level Bio is a public company listed on NGM. |
| What is the stock symbol of Level Bio? | Level Bio trades under LEVBIO ticker. |
| When did Level Bio go public? | Level Bio went public in 2024. |
| Who are competitors of Level Bio? | Similar companies to Level Bio include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Level Bio? | Level Bio's current market cap is $2.8M |
| Is Level Bio profitable? | Yes, Level Bio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
